Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting. The company also develops SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; SPR720, an oral antibiotic, which is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone857-242-1600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.98 million
Profitability
Miscellaneous
Employees35
OptionableOptionable
Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions
What is Spero Therapeutics' stock symbol?
Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."
How were Spero Therapeutics' earnings last quarter?
Spero Therapeutics Inc (NASDAQ:SPRO) issued its quarterly earnings data on Thursday, November, 8th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.04. The firm had revenue of $0.66 million for the quarter, compared to analyst estimates of $0.66 million. Spero Therapeutics had a negative net margin of 1,402.91% and a negative return on equity of 52.22%. View Spero Therapeutics' Earnings History.
When is Spero Therapeutics' next earnings date?
What price target have analysts set for SPRO?
4 brokers have issued 1 year target prices for Spero Therapeutics' stock. Their forecasts range from $9.00 to $30.00. On average, they anticipate Spero Therapeutics' share price to reach $23.50 in the next twelve months. This suggests a possible upside of 191.9% from the stock's current price. View Analyst Price Targets for Spero Therapeutics.
What is the consensus analysts' recommendation for Spero Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spero Therapeutics.
Has Spero Therapeutics been receiving favorable news coverage?
Press coverage about SPRO stock has trended very positive on Tuesday, according to InfoTrie. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Spero Therapeutics earned a news sentiment score of 3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are some of Spero Therapeutics' key competitors?
Some companies that are related to Spero Therapeutics include Crinetics Pharmaceuticals (CRNX), Flexion Therapeutics (FLXN), Arvinas (ARVN), Assembly Biosciences (ASMB), CymaBay Therapeutics (CBAY), Collegium Pharmaceutical (COLL), MacroGenics (MGNX), NuCana (NCNA), Zymeworks (ZYME), Obseva (OBSV), BioSpecifics Technologies (BSTC), Theratechnologies (THERF), Prothena (PRTA), Innate Pharma (IPHYF) and GlycoMimetics (GLYC).
Who are Spero Therapeutics' key executives?
Spero Therapeutics' management team includes the folowing people:
- Mr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 38)
- Mr. Joel D. Sendek, CFO & Treasurer (Age 52)
- Ms. Cristina Larkin, Chief Operating Officer (Age 49)
- Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 65)
- Ms. Sharon Klahre, Director of Investor Relations
When did Spero Therapeutics IPO?
(SPRO) raised $75 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.
How do I buy shares of Spero Therapeutics?
Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spero Therapeutics' stock price today?
One share of SPRO stock can currently be purchased for approximately $8.05.
How big of a company is Spero Therapeutics?
Spero Therapeutics has a market capitalization of $138.51 million and generates $1.98 million in revenue each year. The company earns $-38,740,000.00 in net income (profit) each year or ($17.82) on an earnings per share basis. Spero Therapeutics employs 35 workers across the globe.
What is Spero Therapeutics' official website?
How can I contact Spero Therapeutics?
Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]
MarketBeat Community Rating for Spero Therapeutics (NASDAQ SPRO)
MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote "Outperform" if you believe SPRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
